

## PO-001

## Re-do Laparoscopic Common Bile Duct Exploration For Recurrent Choledocholithiasis

Seung Jae LEE<sup>1</sup>, Ju Ik MOON<sup>1</sup>, In Seok CHOI\*<sup>1</sup>

<sup>1</sup>Surgery, 건양대학교병원, REPUBLIC OF KOREA

**Background**: Recurrence of choledocholithiasis after laparoscopic common bile duct exploration (LCBDE) is relatively common. However, there has been no studies on the safety and feasibility of redo LCBDE for the treatment of recurrent choledocholithiasis.

**Methods**: This single-center, retrospective study reviewed consecutive patients who underwent LCBDE for choledocholithiasis from January 2004 to December 2020. Patients with pancreatobiliary malignancy and those who underwent other surgical procedure were excluded.

**Results**: Of the 340 included patients, 45 (13.2%) had a recurrence after a mean follow-up period of 24.2 months. Of the 45 patients, 18 underwent re-do LCBDE, 20 underwent endoscopic intervention, 2 underwent radiologic intervention, and 5 underwent observation only. Comparing re-do LCBDE with initial LCBDE showed similar surgical outcomes, in terms of operation time (113.1 vs 107.5 minutes, p = 0.515), estimated blood loss (42.5 vs 49.1 mL, p = 0.661), open conversion rate (2.9 vs 0.0%, p = 0.461), postoperative complication (15.3 vs 22.2%, p = 0.430), and postoperative hospital stay (6.5 vs 6.4 days, p = 0.921). Comparing re-do LCBDE and non-surgical treatment (endoscopic or radiologic), there was no statistically significant differences in post-treatment complication (22.2 vs 13.6%, p = 0.477), hospital stay (6.4 vs7.3 days, p = 0.607), and recurrence (50.0 vs 36.4%, p = 0.385). The clearance rate was higher in re-do LCBDE group than in non-surgical group with marginal significance (100.0 vs 81.8%, p = 0.057).

**Conclusions**: Re-do LCBDE for recurrent choledocholithiasis is a treatment option worth considering in selected patients compared to initial LCBDE and endoscopic or radiologic treatment.

Corresponding Author: In Seok CHOI (choiins@kyuh.ac.kr)